IL6ST
IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Colorectal cancer and 1 more.
Overview
Functions as a shared signal-transducing subunit not only for IL6 but also for other cytokine receptor complexes, including IL6, LIF, OSM, CNTF, IL11, CTF1, BSF3, MT-RNR2/humanin, CLCF1 and the heterodimeric complex CRLF1-CLCF1. Engages site 2 of CNTF, CLCF1, LIF, and IL-6, and site 3 of IL27 and IL6. Initiates signal transmission through three mechanisms.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes affected pathway 0.31, literature 0.95, genetic association 0.00, somatic mutation 0.85, animal model 0.57). IntOGen calls it a driver in 4 cohorts (2 activating, 1 loss-of-function), covering Hepatocellular Carcinoma, Prostate Adenocarcinoma, Prostate.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Colorectal cancer and 1 more.
- 1 · What it is
IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Colorectal cancer and 1 more.
- 2 · What goes wrong in cancer
Functions as a shared signal-transducing subunit not only for IL6 but also for other cytokine receptor complexes, including IL6, LIF, OSM, CNTF, IL11, CTF1, BSF3, MT-RNR2/humanin, CLCF1 and the heterodimeric complex CRLF1-CLCF1.
- 3 · How drugs use it
No product in this corpus aims at IL6ST yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:6021 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P40189 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000134352 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: colorectal cancer 0.55, skin cancer 0.52 (GraphQL API, CC0)); IntOGen IL6ST (driver in 4 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Functions as a shared signal-transducing subunit not only for IL6 but also for other cytokine receptor complexes, including IL6, LIF, OSM, CNTF, IL11, CTF1, BSF3, MT-RNR2/humanin, CLCF1 and the heterodimeric complex CRLF1-CLCF1. Engages site 2 of CNTF, CLCF1, LIF, and IL-6, and site 3 of IL27 and IL6. Initiates signal transmission through three mechanisms. Binding of cytokines, such as IL6 or IL11 to the alpha-chains of their specific cell surface receptor triggers homodimerisation of IL6ST/gp130. In contrast, binding of other IL-6 family cytokines can result in the formation of a IL6ST/gp130 heterodimer with another signal-transducing receptor, such as LIFR or OSMR. Moreover, binding of CNTF or CLCF1 or the heterodimeric complex CRLF1-CLCF1 or MT-RNR2/humanin to the non-signalling receptor CNTFR induces heterodimerisation of the IL6ST/gp130 with LIFR or IL27RA/WSX1 (in the case of MT-RNR2/humanin). Location: Cell membrane; Secreted (UniProt). Locus 5q11.2 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC)
- Prostate cancer: IntOGen driver in 2 cohorts (PRAD, PROSTATE)
- Colorectal cancer: Open Targets association 0.55 with colorectal cancer (MONDO_0005575)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"IL6ST" OR ABSTRACT:"IL6ST" OR TITLE:"interleukin 6 cytokine family signal transducer" OR ABSTRACT:"interleukin 6 cytokine family signal transducer" OR TITLE:"Interleukin-6 receptor subunit beta" OR ABSTRACT:"Interleukin-6 receptor subunit beta" OR TITLE:"GP130" OR ABSTRACT:"GP130" OR TITLE:"CD130" OR ABSTRACT:"CD130" OR TITLE:"sGP130" OR ABSTRACT:"sGP130") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IL6ST, not a curated reading list.